Total Payments
$10,190
2020 Payments
$4,524
Companies
1
Transactions
8
Payment Breakdown by Category
Other$5,666 (55.6%)
Research$4,524 (44.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,666 | 5 | 55.6% |
| Unspecified | $4,524 | 3 | 44.4% |
Payments by Type
General
$5,666
5 transactions
Research
$4,524
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $10,190 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $4,524 | 3 | F. Hoffmann-La Roche AG ($4,524) |
| 2019 | $5,666 | 5 | F. Hoffmann-La Roche AG ($5,666) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/06/2020 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,281.07 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $548.64 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $2,694.58 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,996.36 | General |
| Category: BioOncology | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $914.92 | General |
| Category: None | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $442.40 | General |
| Category: None | ||||||
| 06/30/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $945.46 | General |
| Category: None | ||||||
| 03/31/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $366.62 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 | F. Hoffmann-La Roche AG | $3,243 | 2 |
| AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | F. Hoffmann-La Roche AG | $1,281 | 1 |
About Dr. Neal Meropol, MD
Dr. Neal Meropol, MD is a Specialist healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629095153.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neal Meropol, MD has received a total of $10,190 in payments from pharmaceutical and medical device companies, with $4,524 received in 2020. These payments were reported across 8 transactions from 1 company. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($5,666).
Ad
Practice Information
- Specialty Specialist
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Brooklyn, NY
- Active Since 07/17/2006
- Last Updated 02/03/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1629095153
Products in Payments
- ROZLYTREK (Biological) $3,243
- TECENTRIQ (Biological) $2,996
- Non-Covered Product (Drug) $2,669
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Brooklyn
Idan Sharon, M.d, M.D
Specialist — Payments: $2.3M
Specialist $2.3M
Dr. Sean Studer, M.d, M.D
Specialist — Payments: $411,591
Specialist $411,591
Dr. Michael Lewis, M.d, M.D
Specialist — Payments: $68,268
Specialist $68,268
Dr. Marc Avram, Md, MD
Specialist — Payments: $48,018
Specialist $48,018
Michael Amoashiy, Md, MD
Specialist — Payments: $41,408
Specialist $41,408
Dr. Madhavi Reddy, M.d, M.D
Specialist — Payments: $40,649
Specialist $40,649